HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup
The Week

Merck touts Keytruda front-line win in endometrial cancer subtype, marking a PD-1 first

Merck & Co.'s almighty Keytruda has become the first PD-1 inhibitor to show a benefit as a single agent for the front-line treatment of a subtype of endometrial cancer.

By FiercePharma · Jul 16, 2026 · via FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFiercePharma
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFierceBiotech ↗
Vogenx joins the IPO queue to fund phase 2-stage metabolic drug
Vogenx has joined the growing queue for the Nasdaq, as the metabolic biotech eyes an IPO to fund its SGLT1 inh…
Jul 16, 2026
Biogen’s Mid-Stage Alzheimer’s Readout Matches Approved Drugs
The WeekBriefing
Biogen’s Mid-Stage Alzheimer’s Readout Matches Approved Drugs
Biogen reported mid-stage trial data showing its Alzheimer’s drug slowed cognitive decline at rates similar to…
Jul 16, 2026
STAT+: Amylyx nears pivotal endocrine drug study readout
The WeekSTAT News ↗
STAT+: Amylyx nears pivotal endocrine drug study readout
Amylyx Pharmaceuticals will soon read out results from a study evaluating a new treatment for a rare endocrine…
Jul 16, 2026